Expression of phospho-Akt and PTEN proteins predicts the survival of patients with pancreatic cancer

Yonago Acta Medica

Volumn 49, Issue 1, 2006, Pages 9-17

  Ozaki Ohgami, Yoshimi ^a   Iwamoto, Akemi ^a   Yoshioka, Shizue ^a   Tatebe, Shigeru ^a   Hirooka, Yasuaki ^a   Ikeguchi, Masahide ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Pancreatic cancer; Phosphatase and tensin homologue deleted on chromosome ten; Phosphorylated Akt

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL KINASE; PROTEIN KINASE B;

ADULT; AGED; ARTERY; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS TUMOR; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 33645368820     PISSN: 05135710     EISSN: 05135710     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997:7;261-269.
2. Balendran A, Casamayor A, Deak M, Paterson A, Gaffney P, Currie R, et al. PDK1 acuires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999:9;393-404.
3. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002:2;897-909.
4. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001:61;3986-3997.
5. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, NcConkey DJ. Inhibition of the phoshatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vivo and in vitro. Mol Cancer Ther 2002:12;989-997.
6. Burnet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999:96;857-868.
7. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-1321.
8. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL, et al. Inducible nuclear factor-kap-paB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004:199;249-258.
9. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al. Amplificationof AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci 1996:93;3636-3641.
10. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.
11. Di Cristofano A, Pandol. PP. The multiple roles of PTEN in tumor suppression. Cell 2000:100;387-390.
12. Ebert MP, Fei G, Schandl L, Mawin C, Dietzmann K, Herrera P, et al. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer 2002:86;257-262.
13. Franke TF, Yang SI, Chan TO, Datta K, Kazlzuskas A, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995:81;727-736.
14. Hinemann V. Present and future treatment of pancreatic cancer. SeminOncol 2002:29;23-31.
15. Itoh N, Semba S, Itoh M, Takeda H, Kawata S, Yamakawa M. Phoshorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002:94;3127-3134.
16. Leslie NR, Downes CP. PTEN: The down side of PI3-kinase signaling. Cell signal 2002:14;285-295.
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, aputative proten tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997:275;1943-1947.
18. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, et al. Immunohistochemical demonstration of Phospho-Akt in high gleason grade prostate cancer. Clin Cancer Res 2002:8;1168-1171.
19. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Selers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer 1999:59;4291-4296.
20. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000:92;924-930.
21. Perez-Tenorio G, Stal O. Activation of Akt/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002:86;540-545.
22. Perren A, Wenig LP, Boag AH, Ziebold U, Thakore K, Dahia PL, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999:155;1253-1260.
23. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cell towards 5-Fluorouracil and gemcitabine is associated with expression of apoptosis-regulation genes. Oncology 2002:62;354-362.
24. Sobin LH, Wittekind Ch. TNM classification of malignant tumuors (6ed.). New York: John Wiley & Sons; 2002. p. 93-96.
25. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dpendent cell survival by the tumor suppressor PTEN. Cell 1998:95;29-39.
26. Tang D, Okada H, Ruland J, Liu L, Stambolic V, Mark TW, et al. Akt is activated in response to an apoptotic signal. J Biol Chem 2001;276:30461-30466.
27. West KA, Sianna-Castillo S, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Update 2002:5;234-248.
28. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000:60;1541-1545.